Ambrx Biopharma Inc. (AMAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMAM Stock Price Chart Interactive Chart >
AMAM Price/Volume Stats
|Current price||$4.06||52-week high||$22.87|
|Prev. close||$4.00||52-week low||$3.33|
|Day high||$4.35||Avg. volume||11,592|
|50-day MA||$4.09||Dividend yield||N/A|
|200-day MA||$8.70||Market Cap||156.67M|
Ambrx Biopharma Inc. (AMAM) Company Bio
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the Ã and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.
Most Popular Stories View All
AMAM Latest News Stream
|Loading, please wait...|
AMAM Latest Social Stream
View Full AMAM Social Stream
Latest AMAM News From Around the Web
Below are the latest news stories about Ambrx Biopharma Inc that investors may wish to consider to help them evaluate AMAM as an investment opportunity.
SAN DIEGO, February 15, 2022--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced it received a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) related to an Investigational New Drug (IND) application for ARX305, an antibody drug conjugate (ADC) designed to target CD70 to treat a broad range of solid and hematologic tumors su
SAN DIEGO, February 07, 2022--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Paul V. Maier to its Board of Directors and as Chair of the Audit Committee.
Ambrx Biopharma (AMAM) has been struggling lately, but the selling pressure may be coming to an end soon.
Ambrx Biopharmas (NYSE:AMAM) lock-up period is set to expire on Wednesday, December 15th. Ambrx Biopharma had issued 7,000,000 shares in its IPO on June 18th. The total size of the offering was $126,000,000 based on an initial share price of $18.00. After the end of the companys lock-up period, company insiders and major shareholders will 
Ambrx Biopharmas (NYSE:AMAM) lock-up period will end on Wednesday, December 15th. Ambrx Biopharma had issued 7,000,000 shares in its public offering on June 18th. The total size of the offering was $126,000,000 based on an initial share price of $18.00. After the end of Ambrx Biopharmas lock-up period, major shareholders and company insiders will be 
AMAM Price Returns